University Centres and Units

Permanent URI for this community

https://scholar.sun.ac.za/handle/10019.1/258

Browse

Browsing University Centres and Units by Author "Abd El-Kreem, H."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    The Magpie Trial: A randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months
    (2007) Duley, L.; Farrell, B.; Armstrong, N.; Spark, P.; Roberts, B.; Smyth, R.; Tivnan, M.; Laws, A.; Corfield, N.; Salte, A.; Thorn, L.; Altman, D.; Yu, L. M.; Abalos, E.; Carroli, B.; Dellepiane, L.; Duarte, M.; Fernandez, H.; Giordano, D.; Clarke, M.; Gray, A.; Hey, E.; Neilson, J.; Simon, J.; Doyle, L.; Kelly, T.; Squires, J.; Collins, R.; Karaoglou, A.; Lilford, R.; Moodley, J.; Robson, S.; Roberts, I.; Rubin, P.; Thornton J.; Twaddle, S.; Villar, J.; Walker, I.; Watkins, C.; Bimbashi, A.; Demalia, E.; Gliozheni ,O.; Shpata, A.; Karolinski, A.; Lamas, M.; Pesaresi, M.; Wainer, V.; Barbato, W.; Paciocco, M.; Bertin, M.; Boiza, E.; Castaldi, J.; Partida, Y.; Arias, C.; Farri, M.; Kerz, G.; Aguirre, J.; De Sagastizabal, M.; Falcone, R.; Morales, E.; Carroli, G.; Krupitzky, S.; Lopez, S.; Palermo, M.; Montes, Varela D.; Delprato, H.; Camusso, H.; Curioni, M.; Ludmer, E.; Brandi, R.; Martin, R.; Mesas, W.; Taralli, R.; Lezaola, M.; Morosini, M.; Andina, E.; Bernal, L.; Estiu, M.; Ulens, E.; Ortiz De Speranza, B.; Peyrano, A.; Damiano, M.; Saumench, C.; Horn, J.; Pritchard, M.; Smith-Orr, V.; Wilson, M.; Lawrence, A.; Watson, D.; Crowther, C.; Paynter, J.; Ashrafunnessa,; Mannan, M.; Shahidullah, M.; Shamsuddin, L.; Barros, Santos C.; Freire, S.; Melo, E.; Cobo, E.; Jaramillo, E.; Cardozo, C.; Fandino, N.; Gaitan, H.; Montano, L.; Lozano, J.; Rojas, M.; Breto, Garcia A.; Fuentes, Ramirez A.; Garcia, Miras R.; Sampera, S.; Farnot, U.; Gomez, E.; Rojas, G.; Valdes, R.; Abd El-Kreem, H.; Al-Hussaini, T.; Hammad, E.; Danso, K.; Kwapong, E.; Ofosu-Barko, E.; Padmini, Jasper M.; Peedicayil, A.; Regi, A.; Sharma, R.; Chauhan, A.; Raut, V.; Udani, R.; Batra, S.; Muthal-Rathore, A.; Ramji, S.; Zutshi, V.; Balakrishnan, S.; Eapen, E.; Koshy, G.; Ambardar, N.; Vadakkepat, P.; Vaidya, D.; Lema, V.; Rijken, Y.; Tadesse, E.; Dada, O.; Sofekun, A.; Ohiaeri, C.; Runsewe-Abiodun, T.; Adewole, I.; Adeyemo, A.; Brown, B.; Oladokun, R.; Adewale, O.; Inimgba, N.; John, C.; Ogu, R.; Ekele, B.; Isah, A.; Onankpa, B.; Jamelle, R.; Junejo, D.; Ruby, Faiz N.; Gul, F.; Sherin, A.; Bangash, K.; Mahmud, G.; Masud, K.; Tasneem, N.; Gassama, S.; Soyei, A.; Agarwal, P.; Rajadurai, V.; Pirani, N.; Delport, S.; Macdonald, P.; Mokhondo, R.; Pattinson, R.; Zondo, M.; Adhikari, M.; Mnguni, N.; Moodley, J.; Carstens, M.; Kirsten, G.; Steyn, W.; Van Zyl, J.; Helwig, A.; Jacobson, S. L.; Panosche, R.; Hammond, E.; Masanganise, L.
    Objective: To assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia. Design: Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998-2001 ISRCTN 86938761), which compared magnesium sulphate with placebo. Setting: Follow-up of children born at 125 centres in 19 countries across five continents. Population: A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow-up, of whom 3283 (73%) were contacted. Methods: Assessment by questionnaire, with interview and neurodevelopmental testing of selected children. Main outcome measures: Death or neurosensory disability at age of 18 months. Results: Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90-1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40-1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities. Conclusions: The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months. © RCOG 2006 BJOG An International Journal of Obstetrics and Gynaecology.
  • No Thumbnail Available
    Item
    The Magpie Trial: A randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years
    (2007) Duley, L.; Farrell, B.; Armstrong, N.; Spark, P.; Roberts, B.; Smyth, R.; Tivnan, M.; Laws, A.; Corfield, N.; Salter, A.; Thorn, L.; Altman, D.; Yu, L.-M.; Abalos, E.; Carroli, B.; Dellepiane, L.; Duarte, M.; Fernandez, H.; Giordano, D.; Clarke, M.; Gray, A.; Hey, E.; Neilson, J.; Simon, J.; Collins, R.; Karaoglou, A.; Lilford, R.; Moodley, J.; Robson, S.; Roberts, I.; Rubin, P.; Thornton, J.; Twaddle, S.; Villar, J.; Walker, I.; Watkins, C.; Doyle, L.; Bimbashi, A.; Demalia, E.; Gliozheni, O.; Shpata, A.; Karolinski, A.; Lamas, M.; Pesaresi, M.; Wainer, V.; Barbato, W.; Paciocco, M.; Bertin, M.; Boiza, E.; Castaldi, J.; Partida, Y.; Arias, C.; Farri, M.; Kerz, G.; Aguirre, J.; De Sagastizabal, M.; Falcone, R.; Morales, E.; Carroli, G.; Krupitzky, S.; Lopez, S.; Palermo, M.; Montes, Varela D.; Delprato, H.; Camusso, H.; Curioni, M.; Ludmer, E.; Brandi, R.; Martin, R.; Mesas, W.; Taralli, R.; Lezaola, M.; Morosini, M.; Andina, E.; Bernal, L.; Estiu, M.; Ulens, E.; Ortiz De Speranza, B.; Peyrano, A.; Damiano, M.; Saumench, C.; Horn, J.; Pritchard, M.; Smith-Orr, V.; Wilson, M.; Lawrence, A.; Watson, D.; Crowther, C.; Paynter, J.; Ashrafunnessa,; Mannan, M.; Shahidullah, M.; Shamsuddin, L.; Barros Santos, C.; Freire, S.; Melo, E.; Cobo, E.; Jaramillo, E.; Cardozo, C.; Fandino, N.; Gaitan, H.; Montano, L.; Lozano, J.; Rojas, M.; Breto Garcia, A.; Fuentes, Ramirez A.; Garcia, Miras R.; Sampera, S.; Farnot, U.; Gomez, E.; Rojas, G.; Valdes, R.; Abd El-Kreem, H.; Al-Hussaini, T.; Hammad, E.; Danso, K.; Kwapong, E.; Ofosu-Barko, E.; Padmini Jasper, M.; Peedicayil, A.; Regi, A.; Sharma, R.; Chauhan, A.; Raut, V.; Udani, R.; Batra, S.; Muthal-Rathore, A.; Ramji, S.; Zutshi, V.; Balakrishnan, S.; Eapen, E.; Koshy, G.; Ambardar, N.; Vadakkepat, P.; Vaidya, D.; Lema, V.; Rijken, Y.; Tadesse, E.; Dada, O.; Sofekun, A.; Ohiaeri, C.; Runsewe-Abiodun, T.; Adewole, I.; Adeyemo, A.; Brown, B.; Oladokun, R.; Adewale, O.; Inimgba, N.; John, C.; Ogu, R.; Ekele, B.; Isah, A.; Onankpa, B.; Jamelle, R.; Junejo, D.; Ruby, Faiz N.; Gul, F.; Sherin, A.; Bangash, K.; Mahmud, G.; Masud, K.; Tasneem, N.; Gassama, S.; Soyei, A.; Agarwal, P.; Rajadurai, V.; Pirani, N.; Delport, S.; Macdonald, P.; Mokhondo, R.; Pattinson, R.; Zondo, M.; Adhikari, M.; Mnguni, N.; Moodley, J.; Carstens, M.; Kirsten, G.; Steyn, W.; Van Zyl, J.; Helwig, A.; Jacobson, S.-L.; Panosche, R.; Hammond, E.; Masanganise, L.
    Objective: The aim of this study was to assess long-term effects for women following the use of magnesium sulphate for pre-eclampsia. Design: Assessment at 2-3 years after delivery for women recruited to the Magpie Trial (recruitment in 1998-2001, ISRCTN 86938761), which compared magnesium sulphate with placebo for pre-eclampsia. Setting: Follow up after discharge from hospital at 125 centres in 19 countries across five continents. Population: A total of 7927 women were randomised at the follow-up centres. Of these women, 2544 were not included for logistic reasons and 601 excluded (109 at a centre where <20% of women were contacted, 466 discharged without a surviving child and 26 opted out). Therefore, 4782 women were selected for follow-up, of whom 3375 (71%) were traced. Methods: Questionnaire assessment was administered largely by post or in a dedicated clinic. Interview assessment of selected women was performed. Main outcome measures: Death or serious morbidity potentially related to pre-eclampsia at follow up, other morbidity and use of health service resources. Results: Median time from delivery to follow up was 26 months (interquartile range 19-36). Fifty-eight of 1650 (3.5%) women allocated magnesium sulphate died or had serious morbidity potentially related to pre-eclampsia compared with 72 of 1725 (4.2%) women allocated placebo (relative risk 0.84, 95% CI 0.60-1.18). Conclusions: The reduction in the risk of eclampsia following prophylaxis with magnesium sulphate was not associated with an excess of death or disability for the women after 2 years. © RCOG 2006 BJOG An International Journal of Obstetrics and Gynaecology.